Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + bendamustine + bortezomib + dexamethasone
- Development stage
- Phase 2
- Lead developer
- French Innovative Leukemia Organisation
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
RiBVD is a combination chemoimmunotherapy regimen consisting of rituximab, bendamustine, bortezomib (Velcade), and dexamethasone. It was developed and evaluated by the French Innovative Leukemia Organisation (FILO) and the Lymphoma Study Association (LYSA) as a first-line treatment for elderly patients (typically older than 65 years) or transplant-ineligible patients with mantle cell lymphoma (MCL). The regimen combines the anti-CD20 monoclonal antibody rituximab, the alkylating agent bendamustine, the proteasome inhibitor bortezomib, and the corticosteroid dexamethasone to achieve high complete response rates and prolonged progression-free survival without the need for rituximab maintenance therapy.
- Other names
- RiBVDRiBVD regimenRiBVD schemarituximab, bendamustine, bortezomib, and dexamethasonerituximab, bendamustine, velcade, and dexamethasone
02
Targets
C1Q (Complement C1q)CD20 (B-lymphocyte antigen CD20)DNAFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)GR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on rituximab + bendamustine + bortezomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + bendamustine + bortezomib + dexamethasone.